Spring Creek Capital’s CERo Therapeutics Warrants CEROW Stock Holding History

Spring Creek Capital’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$11K	–	82
2022 Q1	$11K	Hold	50,000	–	–	﹤0.01%	772
2021 Q4	$22K	Buy	+50,000	New	+$23.1K	﹤0.01%	635

Other funds holding CEROW

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Spring Creek Capital's CEROW Position: Q2 2022 in Review

Spring Creek Capital sold out of CERo Therapeutics Warrants (CEROW) in Q2 2022, closing a stake of 50,000 shares — an estimated $11K sold.

Spring Creek Capital first reported a position in CEROW in Q4 2021 and held it in 2 quarters. The position peaked at $22K in Q4 2021. 41 funds tracked by Wall St. Rank hold CEROW as of Q2 2022.

Spring Creek Capital reported no remaining CERo Therapeutics Warrants position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 50,000 CERo Therapeutics Warrants shares in Q2 2022, an estimated $11K.
Spring Creek Capital first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 2 quarters.
Spring Creek Capital's CERo Therapeutics Warrants position peaked at $22K in Q4 2021.
41 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.